Business Development and Asset Assessment

The high risk/high reward nature of CNS drug discovery and development has led to an increase in partnering activities. Many large pharmaceutical companies have reduced their in house R&D activities and are now looking for attractive in-licensing opportunities. This includes an increased interest in assets that are at an early stage. On the other hand, many start-ups and smaller companies are looking for partners to support later stage clinical development activities. Dr. Schreiber has more than 20 years of experience with CNS R&D at global pharmaceutical companies in Germany, France and the United States with a variety of approaches (New Chemical Entities, Improved Chemical Entities, repurposed drugs). He has extensive experience with the evaluation of licensing opportunities, preparing company presentations and performing due diligence. Moreover, Dr. Schreiber has built an extensive network in the industry that facilitates leveraging this knowledge for his clients. In addition, his experience in senior management at a global CRO means he can guide customer acquisition strategy for service-oriented companies.

Services include:

  1. Direct access to universities, pharma/biotech, start-up’s and investors

  2. Identification, evaluation and selection of potential partnering opportunities

    • Preparation of company presentations

    • Performing due diligence

  3. Competitor analysis and benchmarking strategy

  4. Defining target drug & product profiles

    • Identification and implementation of differentiation strategies

    • For example, the design of animal studies to demonstrate an improved therapeutic window against a competitor compound

  5. Intellectual property strategy and patent writing

    • Identification prior claims

  6. Customer acquisition for service-oriented companies

Back to Services

Today2018-11-15
design: www.biird.nl